Molina Healthcare (MOH) has just posted Q2 2026 results with total revenue of about US$10.9 billion, basic EPS of US$1.17 and net income excluding extra items of US$60 million, setting the tone for how investors will judge the latest move in margins. Over recent quarters the company has seen revenue move between roughly US$10.3 billion and US$11.0 billion while quarterly basic EPS has ranged from a loss of US$3.15 to a gain of US$5.46, giving investors a wide arc of outcomes to weigh against the current print. With the trailing twelve month figures hovering around breakeven on net income, this quarter’s profit puts the spotlight squarely on how durable Molina Healthcare’s margins really are.

See our full analysis for Molina Healthcare.

With the numbers on the table, the next step is to see how this latest earnings profile lines up against the big narratives investors follow around Molina Healthcare’s growth potential, profitability path and risk profile.

TTM profit still slightly in the red

• Over the last 12 months Molina Healthcare generated about US$42.7b of revenue and a net loss of US$7 million, while quarterly net income excluding extra items has swung from a loss of US$160 million in Q4 2025 to a profit of US$60 million in Q2 2026.
• Consensus narrative expects revenue to grow 6.3% a year with margins rising from 0.4% to 1.2%. However, the recent shift from a US$160 million loss in Q4 2025 to US$14 million and then US$60 million of profit means investors will be watching how quickly medical costs and rate adjustments actually line up with that story.
  • Supporters of the consensus view point to the roughly US$800 million of projected annual premium revenue from recent RFP wins and a pipeline of acquisitions as potential earnings drivers on top of the current US$42.7b revenue base.
  • At the same time, the loss recorded over the last 12 months and earlier quarterly profits of US$255 million and US$298 million in 2025 show that margins have been moving around, which keeps the focus on whether discipline on medical costs can really deliver the smoother earnings path analysts are looking for.

Valuation gap versus DCF fair value

• With the share price at US$200.29 and the provided DCF fair value at US$794.87, Molina Healthcare is shown as trading well below that estimate, while its P/S of 0.2x sits far under the 1.4x US healthcare industry average and 2.1x peer average.
• What is interesting for the bullish narrative is that this low P/S and large gap to the US$794.87 DCF fair value sit alongside analyst expectations for earnings to reach about US$619.1 million by 2029. The real test is whether contract wins and cost control can turn a trailing US$7 million loss into the kind of profit base that would justify both the 212.18 analyst price target and any perceived discount.
  • Bulls highlight that forecasts in the dataset call for earnings growth of 46.47% a year and an eventual move to profitability. If this is achieved on top of current low multiples, it would heavily support the idea that the current share price undervalues that path.
  • On the other hand, critics point to the trailing unprofitability and the fact that losses have grown about 2.1% a year over five years as evidence that the valuation gap only matters if the earnings recovery described by bullish analysts actually shows through in future reported numbers.

For investors who want to see how supporters of a more optimistic case are framing that earnings ramp and margin rebuild, it is worth reading the detailed bullish narrative for Molina Healthcare 🐂 Molina Healthcare Bull Case.

Bear concerns around growth and medical costs

• Revenue growth in the dataset is given as 7.6% a year versus a 12.8% figure for the broader US market, and over the last 12 months Molina Healthcare moved from profits earlier in 2025 to a small loss, with losses described as having grown about 2.1% a year over five years.
• Bears argue that this combination of slower revenue growth than the market, a trailing loss, and recent insider selling makes the business vulnerable if medical costs stay high and government funding tightens. The shift from US$883 million of TTM net income at one point in 2025 to a US$7 million loss by Q2 2026 gives them concrete fuel for that concern.
  • The cautious narrative also flags that revenue is projected at 7.6% growth against 12.8% for the US market, which, together with reliance on Medicaid and Medicare contracts, would limit earnings flexibility if reimbursement formulas or eligibility rules move against the company.
  • At the same time, the current P/S of 0.2x and the large gap to the US$794.87 DCF fair value mean any further pressure on margins or contract terms could weigh on how much comfort investors take from valuation alone, especially if insider selling seen over the past three months continues.

For a closer look at how more cautious investors connect these figures to contract risk, medical cost trends, and future earnings power, you can review the detailed bearish narrative on Molina Healthcare 🐻 Molina Healthcare Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Molina Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of optimism and concern around Molina Healthcare, it makes sense to look through the underlying data yourself and decide what stands out most. Then weigh the company’s 3 key rewards and 1 important warning sign using the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Molina Healthcare still carries a trailing loss, volatile margins and slower revenue growth than the broader US market, which leaves some investors uneasy about future earnings stability.

If those swings in profitability and concern around contract driven revenue leave you wanting steadier businesses, it is worth checking companies in the 79 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.